The anti-Covid vaccine developed by the German laboratory CureVac showed an effectiveness of only 48% according to the final results of phase 3 of the clinical trials.
- This vaccine uses messenger RNA technology, like Pfizer and Moderna.
- The effectiveness would reach 53% among 18 – 60 year olds, its protective effect against moderate and severe forms of the disease climbs to 77% and even up to 100% in the prevention of hospitalizations and deaths.
- The European Medicines Agency (EMA) must study the marketing of this vaccine.
It is a new candidate who disappoints. The German laboratory CureVac presented the final results of its candidate vaccine against Covid-19 on Wednesday and these are proving to be of low effectiveness. This amounts to 48% to prevent Covid-19. Predictable results after the mid-June publication of disappointing interim analyses. This vaccine uses messenger RNA technology, like Pfizer and Moderna.
Effective in 18 – 60 year olds
This vaccine, assures the company, is not devoid of interest and presents good results for the age group of 18-60 years. The effectiveness would reach 53% but, above all, the protective effect against moderate and severe forms of the disease climbs to 77% and even up to 100% in the prevention of hospitalizations and deaths, the laboratory indicated in a statement. “In participants over the age of 60, representing 9% of the cases studied, the available data did not allow a statistically clear determination of efficacy.”, he adds.
The laboratory is convinced that these results are sufficient to play a role in this health crisis. “The vaccine makes a valuable contribution to public health by fully protecting study participants between the ages of 18 and 60 against hospitalization or death, and with a 77% efficacy rate against moderate and severe disease progression. diseaseassures its CEO Franz-Werner Haas, quoted in the press release. We believe this efficacy profile represents an important contribution to managing the Covid-19 pandemic and managing the dynamic spread of variants..”
It’s up to the EMA to decide
CureVac has signed a major order contract with the European Union for the purchase of 405 million doses. It is now up to the European Medicines Agency (EMA) to study the marketing of this vaccine. For comparison, the BioNTech/Pfizer and Moderna vaccines have demonstrated efficacy of around 95%. That of the AstraZeneca and Johnson and Johnson vaccines is between 60 and 70%.
.
